In vitro activity of AZD0914, a novel DNA gyrase inhibitor, against Chlamydia trachomatis and Chlamydia pneumoniae.
dc.contributor.author | Kohlhoff, Stephan A | |
dc.contributor.author | Huband, Michael D | |
dc.contributor.author | Hammerschlag, Margaret R | |
dc.date.accessioned | 2023-07-05T18:46:44Z | |
dc.date.available | 2023-07-05T18:46:44Z | |
dc.date.issued | 2014-12 | |
dc.identifier.citation | Kohlhoff SA, Huband MD, Hammerschlag MR. In vitro activity of AZD0914, a novel DNA gyrase inhibitor, against Chlamydia trachomatis and Chlamydia pneumoniae. Antimicrob Agents Chemother. 2014 Dec;58(12):7595-6. doi: 10.1128/AAC.03920-14. Epub 2014 Oct 6. PMID: 25288086; PMCID: PMC4249501. | en_US |
dc.identifier.eissn | 1098-6596 | |
dc.identifier.doi | 10.1128/AAC.03920-14 | |
dc.identifier.pmid | 25288086 | |
dc.identifier.uri | http://hdl.handle.net/20.500.12648/10391 | |
dc.description.abstract | The in vitro activities of AZD0914, levofloxacin, azithromycin, and doxycycline against 10 isolates each of Chlamydia trachomatis and Chlamydia pneumoniae were tested. For AZD0914, the MIC90s for C. trachomatis and C. pneumoniae were 0.25 μg/ml (range, 0.06 to 0.5 μg/ml) and 1 μg/ml (range, 0.25 to 1 μg/ml), respectively, and the minimal bactericidal concentrations at which 90% of the isolates were killed (MBC90s) were 0.5 μg/ml for C. trachomatis (range, 0.125 to 1 μg/ml) and 2 μg/ml for C. pneumoniae (range, 0.5 to 2 μg/ml). | |
dc.language.iso | en | en_US |
dc.relation.url | https://journals.asm.org/doi/epub/10.1128/aac.03920-14 | en_US |
dc.rights | Copyright © 2014, American Society for Microbiology. All Rights Reserved. | |
dc.rights | Attribution-NonCommercial-NoDerivatives 4.0 International | * |
dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/4.0/ | * |
dc.title | In vitro activity of AZD0914, a novel DNA gyrase inhibitor, against Chlamydia trachomatis and Chlamydia pneumoniae. | en_US |
dc.type | Article/Review | en_US |
dc.source.journaltitle | Antimicrobial agents and chemotherapy | en_US |
dc.source.volume | 58 | |
dc.source.issue | 12 | |
dc.source.beginpage | 7595 | |
dc.source.endpage | 6 | |
dc.source.country | United States | |
dc.description.version | VoR | en_US |
refterms.dateFOA | 2023-07-05T18:46:46Z | |
html.description.abstract | The in vitro activities of AZD0914, levofloxacin, azithromycin, and doxycycline against 10 isolates each of Chlamydia trachomatis and Chlamydia pneumoniae were tested. For AZD0914, the MIC90s for C. trachomatis and C. pneumoniae were 0.25 μg/ml (range, 0.06 to 0.5 μg/ml) and 1 μg/ml (range, 0.25 to 1 μg/ml), respectively, and the minimal bactericidal concentrations at which 90% of the isolates were killed (MBC90s) were 0.5 μg/ml for C. trachomatis (range, 0.125 to 1 μg/ml) and 2 μg/ml for C. pneumoniae (range, 0.5 to 2 μg/ml). | |
dc.description.institution | SUNY Downstate | en_US |
dc.description.department | Pediatrics | en_US |
dc.description.degreelevel | N/A | en_US |
dc.identifier.journal | Antimicrobial agents and chemotherapy | |
dc.identifier.issue | 12 | en_US |